NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 116 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,817 | -36.5% | 2,246 | 0.0% | 0.00% | – |
| Q1 2023 | $9,164 | -23.7% | 2,246 | -6.1% | 0.00% | -100.0% |
| Q4 2022 | $12,008 | -61.6% | 2,392 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $31,287 | +2.0% | 2,392 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $30,665 | +16.3% | 2,392 | +38.3% | 0.00% | 0.0% |
| Q1 2022 | $26,367 | -83.9% | 1,729 | -81.3% | 0.00% | -50.0% |
| Q4 2021 | $163,941 | -15.7% | 9,257 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $194,582 | +6.6% | 9,257 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,548 | -22.9% | 9,257 | +13.6% | 0.00% | -25.0% |
| Q1 2021 | $236,833 | -6.3% | 8,147 | -2.3% | 0.00% | 0.0% |
| Q4 2020 | $252,691 | +90.4% | 8,341 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $132,705 | -19.4% | 8,341 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $164,651 | +60.1% | 8,341 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $102,845 | -33.3% | 8,341 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $154,225 | – | 8,341 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |